INVA: Specialty therapeutics and innovative drug delivery drive growth, backed by stable royalties
Specialty therapeutics revenue exceeded $200 million, driven by strong growth in XACDURO and GIAPREZA, with global expansion through partnerships. Nortiva's LYNX platform targets once-monthly dosing, starting with a contraceptive program, while stable royalty streams and strategic capital allocatio…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.